Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
Earnings Data
Report Date
Nov 05, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-1.3Last Year’s EPS
-1.17Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong clinical progress and strategic partnerships. However, uncertainties around regulatory processes and competitive pressures create some challenges. The company is well-positioned financially and operationally to advance its pipeline.Company Guidance
Strong Start to 2025
REGENXBIO reported a strong beginning to the year with significant clinical progress and the potential to transition to a commercial stage with multiple gene therapies.
RGX-121 BLA Submission
The BLA for RGX-121, a potential first gene therapy for MPS II, was submitted under the accelerated approval pathway and is on track for potential FDA approval in the second half of 2025.
Partnership with Nippon Shinyaku
A strategic partnership with Nippon Shinyaku was established to commercialize the neurodegenerative franchise, including RGX-121 and RGX-111.
Advancement of RGX-202 for Duchenne Muscular Dystrophy
RGX-202 pivotal study surpassed 50% enrollment, with strong interest from the patient community. The company plans to submit a BLA in mid-2026.
Manufacturing Innovation Center
The company will start producing RGX-202 commercial supply at its Manufacturing Innovation Center in the third quarter of 2025, capable of producing up to 2,500 doses annually.
Cash Position and Runway
The company ended the quarter with $272 million, an increase from $245 million at the end of 2024, and expects this to fund operations into the second half of 2026.
RGNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RGNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 07, 2025 | $8.23 | $7.90 | -4.01% |
May 12, 2025 | $7.97 | $8.18 | +2.63% |
Mar 13, 2025 | $6.55 | $6.72 | +2.60% |
Nov 06, 2024 | $9.43 | $11.19 | +18.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RegenXBio (RGNX) report earnings?
RegenXBio (RGNX) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).
What is RegenXBio (RGNX) earnings time?
RegenXBio (RGNX) earnings time is at Nov 05, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RGNX EPS forecast?
RGNX EPS forecast for the fiscal quarter 2025 (Q3) is -1.3.